| 000 | 01712 a2200421 4500 | ||
|---|---|---|---|
| 005 | 20250518035430.0 | ||
| 264 | 0 | _c20200416 | |
| 008 | 202004s 0 0 eng d | ||
| 022 | _a1557-3125 | ||
| 024 | 7 |
_a10.1158/1541-7786.MCR-18-1332 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aKurimchak, Alison M | |
| 245 | 0 | 0 |
_aIntrinsic Resistance to MEK Inhibition through BET Protein-Mediated Kinome Reprogramming in NF1-Deficient Ovarian Cancer. _h[electronic resource] |
| 260 |
_bMolecular cancer research : MCR _c08 2019 |
||
| 300 |
_a1721-1734 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 |
_aCell Cycle Proteins _xantagonists & inhibitors |
| 650 | 0 | 4 |
_aDrug Resistance, Neoplasm _xdrug effects |
| 650 | 0 | 4 | _aDrug Therapy, Combination |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aMAP Kinase Kinase 1 _xantagonists & inhibitors |
| 650 | 0 | 4 | _aMAP Kinase Signaling System |
| 650 | 0 | 4 |
_aNeurofibromin 1 _xdeficiency |
| 650 | 0 | 4 |
_aOvarian Neoplasms _xdrug therapy |
| 650 | 0 | 4 |
_aProtein Kinase Inhibitors _xpharmacology |
| 650 | 0 | 4 |
_aReceptor Protein-Tyrosine Kinases _xantagonists & inhibitors |
| 650 | 0 | 4 | _aSignal Transduction |
| 650 | 0 | 4 |
_aTranscription Factors _xantagonists & inhibitors |
| 650 | 0 | 4 | _aTumor Cells, Cultured |
| 700 | 1 | _aShelton, Claude | |
| 700 | 1 | _aHerrera-Montávez, Carlos | |
| 700 | 1 | _aDuncan, Kelly E | |
| 700 | 1 | _aChernoff, Jonathan | |
| 700 | 1 | _aDuncan, James S | |
| 773 | 0 |
_tMolecular cancer research : MCR _gvol. 17 _gno. 8 _gp. 1721-1734 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1158/1541-7786.MCR-18-1332 _zAvailable from publisher's website |
| 999 |
_c29645916 _d29645916 |
||